Summit Therapeutics (SMMT) Competitors $19.00 +0.58 (+3.15%) (As of 11/22/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends SMMT vs. TAK, BNTX, TEVA, BGNE, VTRS, MRNA, GMAB, RDY, PCVX, and CTLTShould you be buying Summit Therapeutics stock or one of its competitors? The main competitors of Summit Therapeutics include Takeda Pharmaceutical (TAK), BioNTech (BNTX), Teva Pharmaceutical Industries (TEVA), BeiGene (BGNE), Viatris (VTRS), Moderna (MRNA), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Vaxcyte (PCVX), and Catalent (CTLT). These companies are all part of the "pharmaceutical products" industry. Summit Therapeutics vs. Takeda Pharmaceutical BioNTech Teva Pharmaceutical Industries BeiGene Viatris Moderna Genmab A/S Dr. Reddy's Laboratories Vaxcyte Catalent Takeda Pharmaceutical (NYSE:TAK) and Summit Therapeutics (NASDAQ:SMMT) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, profitability, analyst recommendations, valuation, risk, community ranking, dividends and institutional ownership. Do insiders & institutionals have more ownership in TAK or SMMT? 9.2% of Takeda Pharmaceutical shares are owned by institutional investors. Comparatively, 4.6% of Summit Therapeutics shares are owned by institutional investors. 0.0% of Takeda Pharmaceutical shares are owned by company insiders. Comparatively, 88.3% of Summit Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Do analysts recommend TAK or SMMT? Summit Therapeutics has a consensus target price of $34.75, indicating a potential upside of 82.89%. Given Summit Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Summit Therapeutics is more favorable than Takeda Pharmaceutical.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Takeda Pharmaceutical 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Summit Therapeutics 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75 Which has more volatility & risk, TAK or SMMT? Takeda Pharmaceutical has a beta of 0.54, suggesting that its stock price is 46% less volatile than the S&P 500. Comparatively, Summit Therapeutics has a beta of -0.92, suggesting that its stock price is 192% less volatile than the S&P 500. Does the media prefer TAK or SMMT? In the previous week, Takeda Pharmaceutical had 2 more articles in the media than Summit Therapeutics. MarketBeat recorded 4 mentions for Takeda Pharmaceutical and 2 mentions for Summit Therapeutics. Takeda Pharmaceutical's average media sentiment score of 0.66 beat Summit Therapeutics' score of 0.20 indicating that Takeda Pharmaceutical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Takeda Pharmaceutical 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Summit Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Does the MarketBeat Community favor TAK or SMMT? Summit Therapeutics received 199 more outperform votes than Takeda Pharmaceutical when rated by MarketBeat users. Likewise, 58.06% of users gave Summit Therapeutics an outperform vote while only 56.82% of users gave Takeda Pharmaceutical an outperform vote. CompanyUnderperformOutperformTakeda PharmaceuticalOutperform Votes10056.82% Underperform Votes7643.18% Summit TherapeuticsOutperform Votes29958.06% Underperform Votes21641.94% Which has preferable valuation and earnings, TAK or SMMT? Takeda Pharmaceutical has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTakeda Pharmaceutical$4.55T0.01$994.06M$0.5823.07Summit Therapeutics$700K20,016.50-$614.93M-$0.28-67.85 Is TAK or SMMT more profitable? Takeda Pharmaceutical has a net margin of 6.49% compared to Summit Therapeutics' net margin of 0.00%. Takeda Pharmaceutical's return on equity of 10.00% beat Summit Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Takeda Pharmaceutical6.49% 10.00% 4.78% Summit Therapeutics N/A -85.42%-52.66% SummaryTakeda Pharmaceutical beats Summit Therapeutics on 11 of the 18 factors compared between the two stocks. Ad DTILet’s be bluntLet me be blunt with you for just a second… You may think you know when and why stocks move, but you’re wrong… Most traders have no idea about the biggest secret Wall Street keeps — even though it’s hiding in plain sight. But once you’ve cracked this code… It could be the breakthrough you need to start targeting $100-$150 a day in the stock market (starting with just $1,000)! Check out the $100 Challenge now Get Summit Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SMMT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SMMT vs. The Competition Export to ExcelMetricSummit TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$14.01B$7.00B$5.38B$8.84BDividend YieldN/A8.11%5.13%4.09%P/E Ratio-67.8511.01105.0417.81Price / Sales20,016.50361.871,235.79158.52Price / CashN/A52.5940.3536.29Price / Book32.2010.377.086.50Net Income-$614.93M$153.60M$119.58M$226.22M7 Day Performance3.77%4.59%2.25%4.03%1 Month Performance-5.14%-6.28%-2.34%4.92%1 Year Performance874.36%33.39%33.95%29.30% Summit Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SMMTSummit Therapeutics1.8568 of 5 stars$19.00+3.1%$34.75+82.9%+874.4%$14.01B$700,000.00-67.85105TAKTakeda Pharmaceutical3.7212 of 5 stars$13.33+0.3%N/A-4.4%$42.41B$28.20B22.9849,281High Trading VolumeBNTXBioNTech2.634 of 5 stars$108.20+5.9%$138.79+28.3%+15.5%$25.94B$4.13B-51.526,133Analyst ForecastTEVATeva Pharmaceutical Industries3.004 of 5 stars$17.08+0.3%$19.67+15.1%+81.0%$19.29B$16.77B-20.0937,851Insider TradeBGNEBeiGene3.1896 of 5 stars$194.56+0.2%$247.07+27.0%+4.2%$18.92B$3.32B-23.6110,600Analyst DowngradeVTRSViatris1.4394 of 5 stars$13.26+0.9%$13.33+0.6%+42.7%$15.82B$15.43B-17.9138,000News CoverageMRNAModerna4.5706 of 5 stars$38.40+4.0%$84.00+118.7%-47.4%$14.78B$6.85B-6.605,600Analyst ForecastOptions VolumeAnalyst RevisionGMABGenmab A/S4.232 of 5 stars$20.47+0.1%$45.20+120.8%-34.5%$13.55B$2.39B19.872,204High Trading VolumeRDYDr. Reddy's Laboratories1.4214 of 5 stars$13.99-2.2%$17.00+21.5%+5.0%$11.68B$3.35B22.3527,048PCVXVaxcyte3.3258 of 5 stars$88.39+2.8%$147.50+66.9%+80.7%$11.02BN/A-19.22160Positive NewsHigh Trading VolumeCTLTCatalent3.0832 of 5 stars$59.66+1.1%$63.40+6.3%+54.0%$10.83B$4.38B-26.4016,900Analyst Downgrade Related Companies and Tools Related Companies Takeda Pharmaceutical Competitors BioNTech Competitors Teva Pharmaceutical Industries Competitors BeiGene Competitors Viatris Competitors Moderna Competitors Genmab A/S Competitors Dr. Reddy's Laboratories Competitors Vaxcyte Competitors Catalent Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SMMT) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Summit Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Summit Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SMMT Stock Alerts